For Providers — Meningitis B Action Project
Public Health Agency on X: "If your planning on going to university or college make sure your teenage immunisations are up-to-date. It's also worth checking if you got your MMR and HPV.
MenB booster research | Meningitis Research Foundation
ACIP recommendations for COVID-19 vaccines—and more | MDedge Family Medicine
Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods - ScienceDirect
Adolescent Vaccination
ACIP provides recommendations on meningococcal vaccination
![MENVEO (Meningococcal [Groups A,C,Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) | Home](https://gskpro.com/content/dam/global/hcpportal/en_US/img/menveo/hero-mobile-image.png "MENVEO (Meningococcal [Groups A,C,Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) | Home")
MENVEO (Meningococcal [Groups A,C,Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) | Home
:max_bytes(150000):strip_icc()/Meningococcal-vaccine-5215620_final_05-063b0877ce5c401ca3a0545a27ca6e3c.jpg "Meningococcal Vaccine: Protection, Risk, Schedule")
Meningococcal Vaccine: Protection, Risk, Schedule
Full article: Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
Meningitis booster vaccine now required for high school seniors | News | wataugademocrat.com
NHS North Central London on X: "The MenACWY vaccine is routinely given in school years 9-10, at the same time as the 3-in-1 booster. Together they protect against tetanus, diphtheria, polio, meningitis,
Parents and Teens – National Meningitis Association
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years | BMC Infectious Diseases
Meningococcal Vaccination | CDC
![Meningococcal Conjugate Vaccine | Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)](https://www.menactra.com/_assets/img/menactra-web-timeline-art-mobile.jpg "Meningococcal Conjugate Vaccine | Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)")
Meningococcal Conjugate Vaccine | Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)
![Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]](https://www.menveohcp.com/content/dam/cf-pharma/hcp-menveo/en_US/booster/2-vial-seroresponse-rates-29-days-Mobile.svg "Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]")
Immunogenicity Booster | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]
Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV — United States, 2022 | MMWR
MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults - ScienceDirect
Schedule for Booster Doses in | Download Table
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years | BMC Infectious Diseases
Immunisation for teenagers between 14 and 18 years old | nidirect
